[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019172714A1 - Functional food composition for enhancing muscular function and mobility and comprising chamomile extract, and method for preparing same - Google Patents

Functional food composition for enhancing muscular function and mobility and comprising chamomile extract, and method for preparing same Download PDF

Info

Publication number
WO2019172714A1
WO2019172714A1 PCT/KR2019/002740 KR2019002740W WO2019172714A1 WO 2019172714 A1 WO2019172714 A1 WO 2019172714A1 KR 2019002740 W KR2019002740 W KR 2019002740W WO 2019172714 A1 WO2019172714 A1 WO 2019172714A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
food composition
functional food
function
chamomile extract
Prior art date
Application number
PCT/KR2019/002740
Other languages
French (fr)
Korean (ko)
Inventor
김진학
장지환
금정호
권민선
최수영
김상우
황재관
Original Assignee
주식회사 뉴트리사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 뉴트리사이언스 filed Critical 주식회사 뉴트리사이언스
Publication of WO2019172714A1 publication Critical patent/WO2019172714A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction

Definitions

  • the present invention relates to a muscle function and exercise-enhancing functional food composition comprising a chamomile extract and a method of manufacturing the same.
  • chamomile is Chamaemelum nobile, Matricaria It has the same scientific name as chamomilla, and the generic name Matricaria is Latin for 'matrix', which is derived from the effect of gynecological diseases. It is known to be mainly used in car, bathing, beauty, poultice, etc., and is effective for insect repellent, soothing, dysmenorrhea, pain relief, sweating, promoting digestion, and fatigue recovery.
  • the Chinese medicine refers to the effects of cardiovascular disease, cold, diarrhea, eczema, hemorrhagic cystitis, hemorrhoids, infant colic, soothing, vaginitis, wound healing.
  • the present inventors have completed the present invention by checking the effect of the composition containing the chamomile extract to improve muscle function and motor activity while studying the material originating from natural products.
  • An object of the present invention is to provide a functional food composition for strengthening muscle function and exercise performance.
  • a functional food composition for strengthening muscle function and exercise including chamomile extract.
  • the present invention may comprise more than 0% by weight to 100% by weight of chamomile extract based on the total weight of the composition.
  • composition for the prevention or amelioration of muscle-related diseases atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, It can be used for the prevention or amelioration of one or more selected from the group consisting of amyotrophic lateral sclerosis, cachexia, sarcopenia.
  • a method for producing muscle function and strengthening functional food composition comprising the step of extracting chamomile in water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent. can do.
  • the method may include obtaining chamomile extract from chamomile by subcritical extraction, supercritical fluid extraction, or ultrahigh pressure extraction.
  • the functional food composition and method for enhancing muscle function and the production method according to the present invention it is possible to improve the production of factors related to energy metabolism and muscle production, and as a result can provide a composition that can improve the exercise ability and muscle function .
  • it can be applied to various fields such as food as a health functional composition.
  • 1 is a graph showing the activity of mTOR according to the embodiment.
  • FIG. 2 is a graph showing the activity of PPAR ⁇ according to the embodiment.
  • FIG. 3 is a graph showing the activity of PGC-1 ⁇ according to the embodiment.
  • Figure 4 is an electrophoresis picture showing the muscle protein degradation inhibitory activity according to the embodiment.
  • 5 is an electrophoretic photograph showing mitochondrial biosynthesis and muscle differentiation activity according to the embodiment.
  • muscle function and motor function enhancement 'means improving the activity of mTOR, PPAR ⁇ and PGC-1 ⁇ , inhibiting the degradation of muscle protein, promoting the biosynthesis of mitochondria, and promoting muscle differentiation. .
  • inhibition of muscle protein degradation may be confirmed by the reduction of mRNA expression of atrogin-1 and MuRF-1.
  • mitochondrial biosynthesis promotion and muscle differentiation promoting activity can be confirmed that the mRNA expression of myogenin, NRF1, Tfam is increased.
  • muscle function and exercise ability by strengthening muscle function and exercise ability, it is possible to prevent, treat and improve muscle-related diseases. Prevention, treatment and improvement of muscle related diseases can be confirmed by expression of muscle and exercise related factors such as mTOR, PPAR ⁇ and PGC-1 ⁇ .
  • Muscle-related diseases may include diseases due to decreased muscle function, muscle wasting, muscle degeneration and the like. Specifically, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, amyotrophic lateral sclerosis, cachexia Can prevent, treat and ameliorate diseases such as sarcopenia.
  • the muscle function and exercise enhancing functional food composition according to the present invention includes chamomile extract.
  • the present invention may comprise more than 0% to 100% by weight of chamomile extract, for example 1 to 100% by weight, for example 20 to 70% by weight relative to the total weight of the composition.
  • the muscle function and motor function-enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract with water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent.
  • the organic solvent having 1 to 6 carbon atoms may include methanol, ethanol, ethyl acetate, hexane, and the like.
  • the composition according to the invention may be prepared by a method comprising the step of extracting alcohol or hot water extracted for chamomile.
  • 10-95%, for example 20-80%, for example 50% alcohol may be used in the alcohol extraction step.
  • it may include the step of extracting the alcohol by adding 2 to 20 times the volume of the extraction target. It may also be extracted for example for 0.5 to 10 hours, for example 2 to 5 hours, for example at 4 to 80 ° C, for example 20 to 70 ° C, for example 40 to 60 ° C. Can be.
  • the hydrothermal extraction step may include extracting by adding 2 to 20 times the volume of the extraction target volume of water. It can also be extracted for example for 0.5 to 12 hours, for example 2 to 6 hours, for example at 4 to 121 ° C, for example 50 to 121 ° C, for example 80 to 121 ° C. Can be.
  • the muscle function and exercise enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract from chamomile using subcritical extraction, supercritical fluid extraction or ultrahigh pressure extraction.
  • Chamomile extract was obtained in the same manner as in Example 2 except that methanol was used.
  • Chamomile extract was obtained in the same manner as in Example 2, except that ethyl acetate was used.
  • Chamomile extract was obtained in the same manner as in Example 2 except that hexane was used.
  • Chamomile 18%, ethanol 76mL was put in a polyethylene pack and sealed and extracted using an ultrahigh pressure extractor (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan).
  • the extraction pressure was set to 320MPa and the extraction time was 5 minutes as the ultrahigh pressure extraction condition.
  • the extracted sample was filtered and concentrated to remove the extraction solvent, and lyophilized to obtain a chamomile extract.
  • Chamomile was charged to a sample cartridge and extracted using a supercritical extractor (SFX 3560, Isco Inc., Lincoln, NE, USA).
  • Supercritical fluid extraction conditions were set to extraction pressure 20MPa, extraction temperature 60 °C, flow rate of supercritical carbon dioxide 60mL / min, extraction time 60 minutes.
  • the pressure of the extractor was lowered to release the supercritical fluid state to obtain a chamomile extract.
  • mTOR activity for each extract according to Example 1 was evaluated.
  • mTOR is a protein that plays a role in regulating the mechanism of muscle protein synthesis, and can confirm the improvement of muscle mass by confirming the activity of mTOR.
  • a muscle cell master L6 cells 110% fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated.
  • DMEM Hyclone
  • HS horse serum
  • the extract prepared in Example 1 was dissolved in DMEM medium containing 50ng / mL of TNF- ⁇ at a concentration of 100 or 200ug / mL, and then treated to cells. After 6 hours, total RNA was isolated using TRIzol reagent (Takara, Osaka, Japan). Total RNA isolated was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, Mass., USA. The results are shown in Table 1.
  • COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) in a 24-well plate at 1 ⁇ 10 5 cells / mL.
  • FBS FBS
  • Lipofector EXT (Aptabio) was used to induce PPAR ⁇ transformation to identify anti-inflammatory effects.
  • each extract was added to the cells together at a concentration of 10 ⁇ g / mL. 24 hours treatment.
  • luciferase activity was evaluated using luciferase assay kit (Promega).
  • PPAR ⁇ is a protein that may be associated with cell differentiation in adipose tissue and sugar production in liver tissue. As a result, PPAR ⁇ may be confirmed to improve motor performance by confirming the activity of PPAR ⁇ . The results are shown in Table 2.
  • COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) to 1 ⁇ 10 5 cells / mL in 24-well plates.
  • FBS peroxisome proliferator-activated receptor gamma coactivator-1 alpha
  • PGC-1 ⁇ peroxisome proliferator-activated receptor gamma coactivator-1 alpha
  • Each extract was treated with cells at a concentration of 10 ⁇ g / mL for 24 hours.
  • luciferase activity was evaluated using luciferase assay kit (Promega).
  • PGC-1 ⁇ is a protein related to glycemic regulation and mitochondrial function replication, which can confirm the improvement of exercise ability by confirming the activity of PGC-1 ⁇ .
  • the results are shown in Table 3.
  • Atrogin-1 is a muscle breakdown protein that is activated when muscle is lost
  • MuRF1 is a muscle degrading enzyme protein
  • ⁇ -actin is a protein that makes up muscle, which causes muscle contraction and relaxation with myosin.
  • L6 cells 110% fetal bovine serum (FBS; Hyclone, Logan, UT , USA) Dulbecco's modified Eagle's media (DMEM; Hyclone) is contained 2 ⁇ 10 in 6-well plates with 5 cell / After inoculation to mL was incubated. When the cell density is about 80-85%, the medium in the wells is removed and exchanged for DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) to convert L6 cells into myotubes. Differentiated. Once every two days, the cells were replaced with fresh medium for a total of six days of differentiation.
  • FBS fetal bovine serum
  • DMEM Dulbecco's modified Eagle's media
  • RNA 16 uL RNA was quantified and mixed with Reverse Transcriptase Premix (ELPIS-Biotech) using a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA) at 42 ° C, 55 minutes, 70 CDNA was synthesized at 15 ° C. for 15 minutes.
  • PCR samples were prepared by mixing 4 uL of the cDNA, specific primer pairs (Bioneer, Deajeon, Korea), and PCR premix (ELPIS-Biotech) below in the synthesized cDNA, and then, at 95 ° C for 30 seconds and at 60 ° C. PCR was performed by repeating 30 minutes for 1 minute at 72 ° C.
  • the cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 4, and the results are shown in FIG.
  • Example 1 In order to confirm the muscle mitochondrial biosynthesis promoting and muscle differentiation promoting activity of Example 1, the expression of myogenin, NRF1 and Tfam was confirmed. Myogenin controls differentiation and maturation into myotubes, NRF1 is involved in mitochondrial protein production, and Tfam is involved in mitochondrial DNA transcription.
  • a muscle cell master L6 cells 110% fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80 to 85%, the medium in the well was removed and the chamomile extract prepared in Example 1 was added to DMEM (Hyclone) containing 2% HS at a concentration of 100 or 200 ug / mL. After thawing, the cells were treated to induce differentiation into root canal cells.
  • ATCC fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80
  • the cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 5, and the results are shown in FIG.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a functional food composition for enhancing muscular function and mobility and a method for preparing same. According to the present invention, provided is a composition which enables increased generation of factors associated with myogenesis and energy metabolism and thus enhances mobility and muscular function. More particularly, mitochondria and muscle cell synthesis is increased and muscular atrophy is inhibited, and thus muscle exercise effects can be increased and fatigue is reduced. The composition can be applied as a health function composition to various fields such as foods.

Description

캐모마일 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법Muscle function and exercise fortifying functional food composition comprising chamomile extract and method for producing same
본 발명은 캐모마일 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a muscle function and exercise-enhancing functional food composition comprising a chamomile extract and a method of manufacturing the same.
최근 과학기술 및 현대 의학의 발달로 인하여 인간의 평균 수명은 점차 증가하고 있으며, 이에 따라 삶의 질 향상을 위하여 건강을 위한 관심이 증가되고 있다. 이러한 경향은 세대와 나이에 상관없이 증가하고 있다. 또한, 천연물을 포함하는 의약품, 건강보조식품 및 화장품에 많은 관심이 증가하면서 이에 대한 연구개발이 증가하고 있는 실정이다. 특히, 천연물 의약품의 효능 및 천연물을 포함하는 건강보조식품과 화장품의 기능은 항산화, 콜레스테롤 억제, 비만 예방 효과, 면역 및 질병예방 및 노화억제 등의 기초 의과학적 범위까지 확대되고 있다.Recently, due to the development of science and modern medicine, the average life expectancy of human beings is gradually increasing, and accordingly, interest for health is increasing to improve the quality of life. This trend is increasing regardless of generation and age. In addition, with the increasing interest in medicines, health supplements, and cosmetics containing natural products, the research and development thereof is increasing. In particular, the efficacy of natural medicines and functions of health supplements and cosmetics containing natural products have been extended to the basic medical range, such as antioxidant, cholesterol suppression, obesity prevention effect, immunity and disease prevention and anti-aging.
천연물에 사용되는 천연 식물 중, 캐모마일(chamomile)은 Chamaemelum nobile, Matricaria chamomilla와 같은 학명을 가지며, 속명의 Matricaria는 라틴어 'matrix(자궁)'이라는 뜻으로, 부인병에 약효가 있는 것에서 유래된 명칭이다. 주로 차로 미시거나 목욕, 미용, 습포 등에 이용하고, 방충, 진정, 진경, 진통, 발한, 소화촉진, 피로회복 등에 효과가 있다고 알려져 있다. 또한, 한의학에서는 심혈관 질환, 감기, 설사, 습진, 출혈성 방광염, 치질, 영아 산통, 진정, 질염, 상처치유 등의 효과를 언급하고 있다.Among the natural plants used for natural products, chamomile is Chamaemelum nobile, Matricaria It has the same scientific name as chamomilla, and the generic name Matricaria is Latin for 'matrix', which is derived from the effect of gynecological diseases. It is known to be mainly used in car, bathing, beauty, poultice, etc., and is effective for insect repellent, soothing, dysmenorrhea, pain relief, sweating, promoting digestion, and fatigue recovery. In addition, the Chinese medicine refers to the effects of cardiovascular disease, cold, diarrhea, eczema, hemorrhagic cystitis, hemorrhoids, infant colic, soothing, vaginitis, wound healing.
본 발명자들은 천연물로부터 기원하는 물질에 관하여 연구하던 중 캐모마일 추출물을 포함하는 조성물이 근기능 및 운동능을 향상시키는 효과를 확인하여 본 발명을 완성하게 되었다.The present inventors have completed the present invention by checking the effect of the composition containing the chamomile extract to improve muscle function and motor activity while studying the material originating from natural products.
본 발명의 목적은 근기능 및 운동능 강화 기능성 식품 조성물을 제공하는 것이다.An object of the present invention is to provide a functional food composition for strengthening muscle function and exercise performance.
본 발명의 다른 목적은 근기능 및 운동능 강화 기능성 식품 조성물을 제조하는 방법을 제공하는 것이다.It is another object of the present invention to provide a method for producing a functional food composition for strengthening muscle function and exercise performance.
상기 과제를 해결하기 위하여, 본 발명은In order to solve the above problems, the present invention
캐모마일 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물을 제공한다.Provided is a functional food composition for strengthening muscle function and exercise, including chamomile extract.
일구현예에 따르면, 본 발명은 조성물 총 중량에 대하여 캐모마일 추출물을 0중량% 초과 100중량% 이하 포함할 수 있다.According to one embodiment, the present invention may comprise more than 0% by weight to 100% by weight of chamomile extract based on the total weight of the composition.
일구현예에 따르면, 근육 관련 질환의 예방 또는 개선용 조성물로서, 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증(myasthenia), 근경직증(myotonia), 근위축성 축삭경화증(amyotrophic lateral sclerosis), 악액질(cachexia), 근육감소증(sarcopenia)으로 이루어지는 군으로부터 선택되는 하나 이상의 예방 또는 개선용으로 사용할 수 있다.According to one embodiment, as a composition for the prevention or amelioration of muscle-related diseases, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, It can be used for the prevention or amelioration of one or more selected from the group consisting of amyotrophic lateral sclerosis, cachexia, sarcopenia.
또한, 본 발명의 다른 구현예에 따르면, 캐모마일에 대하여 물, 탄소수 1 내지 6의 유기용매 또는 이들의 혼합물을 용매로 하여 추출하는 단계를 포함하는 근기능 및 운동능 강화 기능성 식품 조성물의 제조방법을 제공할 수 있다.Further, according to another embodiment of the present invention, there is provided a method for producing muscle function and strengthening functional food composition comprising the step of extracting chamomile in water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent. can do.
또한, 일구현예에 따르면, 캐모마일로부터 아임계 추출법, 초임계 유체 추출법 또는 초고압 추출법으로 캐모마일 추출물을 수득하는 단계를 포함할 수 있다.Further, according to one embodiment, the method may include obtaining chamomile extract from chamomile by subcritical extraction, supercritical fluid extraction, or ultrahigh pressure extraction.
기타 본 발명의 구현예들의 구체적인 사항은 이하의 상세한 설명에 포함되어 있다.Other specific details of embodiments of the present invention are included in the following detailed description.
본 발명에 따른 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법에 따르면, 에너지 대사 및 근육 생성 관련 인자의 생성을 향상시킬 수 있으므로 결과적으로 운동 능력 및 근기능을 향상시킬 수 있는 조성물을 제공할 수 있다. 또한, 건강 기능성 조성물로서 식품 등 다양한 분야에 적용할 수 있다.According to the functional food composition and method for enhancing muscle function and the production method according to the present invention, it is possible to improve the production of factors related to energy metabolism and muscle production, and as a result can provide a composition that can improve the exercise ability and muscle function . In addition, it can be applied to various fields such as food as a health functional composition.
도 1은 실시예에 따른 mTOR의 활성을 나타내는 그래프이다.1 is a graph showing the activity of mTOR according to the embodiment.
도 2는 실시예에 따른 PPARδ의 활성을 나타내는 그래프이다.2 is a graph showing the activity of PPARδ according to the embodiment.
도 3은 실시예에 따른 PGC-1α의 활성을 나타내는 그래프이다.3 is a graph showing the activity of PGC-1α according to the embodiment.
도 4는 실시예에 따른 근 단백질 분해 억제 활성을 나타내는 전기영동 사진이다.Figure 4 is an electrophoresis picture showing the muscle protein degradation inhibitory activity according to the embodiment.
도 5는 실시예에 따른 미토콘드리아 생합성 및 근육분화 활성을 나타내는 전기영동 사진이다.5 is an electrophoretic photograph showing mitochondrial biosynthesis and muscle differentiation activity according to the embodiment.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예를 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.As the present invention allows for various changes and numerous embodiments, particular embodiments will be illustrated in the drawings and described in detail in the written description. However, this is not intended to limit the present invention to specific embodiments, it should be understood to include all transformations, equivalents, and substitutes included in the spirit and scope of the present invention. In the following description of the present invention, if it is determined that the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.
이하, 본 발명의 구현예에 따른 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법에 대하여 보다 상세하게 설명한다.Hereinafter, the muscle function and exercise performance-enhancing functional food composition according to the embodiment of the present invention and a manufacturing method thereof will be described in more detail.
본 명세서에 사용되는 용어 근기능 및 운동능 강화'는 mTOR, PPARδ 및 PGC-1α의 활성을 향상키고, 근 단백질의 분해를 억제시키며, 미토콘드리아의 생합성을 촉진시키고, 근육의 분화를 촉진시키는 것을 의미한다. 구체적으로, 근 단백질 분해 억제는 atrogin-1 및 MuRF-1의 mRNA 발현이 감소하는 것으로 확인할 수 있다. 또한, 미토콘드리아 생합성 촉진 및 근육 분화 촉진 활성은 myogenin, NRF1, Tfam의 mRNA 발현이 증가하는 것으로 확인할 수 있다.As used herein, the term muscle function and motor function enhancement 'means improving the activity of mTOR, PPARδ and PGC-1α, inhibiting the degradation of muscle protein, promoting the biosynthesis of mitochondria, and promoting muscle differentiation. . Specifically, inhibition of muscle protein degradation may be confirmed by the reduction of mRNA expression of atrogin-1 and MuRF-1. In addition, mitochondrial biosynthesis promotion and muscle differentiation promoting activity can be confirmed that the mRNA expression of myogenin, NRF1, Tfam is increased.
일구현예에 따르면, 근기능 및 운동능을 강화시킴으로써 근육 관련 질환을 예방, 치료 및 개선할 수 있다. 근육 관련 질환의 예방, 치료 및 개선은 mTOR, PPARδ 및 PGC-1α 등의 근육 및 운동 관련 인자에 대한 발현으로 확인할 수 있다.According to one embodiment, by strengthening muscle function and exercise ability, it is possible to prevent, treat and improve muscle-related diseases. Prevention, treatment and improvement of muscle related diseases can be confirmed by expression of muscle and exercise related factors such as mTOR, PPARδ and PGC-1α.
근육 관련 질환은 근기능의 저하, 근육의 소모, 근육의 퇴화 등으로 인한 질환을 포함할 수 있다. 구체적으로, 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증(myasthenia), 근경직증(myotonia), 근위축성 축삭경화증(amyotrophic lateral sclerosis), 악액질(cachexia), 근육감소증(sarcopenia) 등의 질환을 예방, 치료 및 개선시킬 수 있다.Muscle-related diseases may include diseases due to decreased muscle function, muscle wasting, muscle degeneration and the like. Specifically, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, amyotrophic lateral sclerosis, cachexia Can prevent, treat and ameliorate diseases such as sarcopenia.
본 발명에 따른 근기능 및 운동능 강화 기능성 식품 조성물은 캐모마일 추출물을 포함한다.The muscle function and exercise enhancing functional food composition according to the present invention includes chamomile extract.
일구현예에 따르면, 본 발명은 조성물 총 중량에 대하여 캐모마일 추출물 0중량% 초과 100중량% 이하, 예를 들어 1 내지 100중량%, 예를 들어 20 내지 70중량%를 포함할 수 있다.According to one embodiment, the present invention may comprise more than 0% to 100% by weight of chamomile extract, for example 1 to 100% by weight, for example 20 to 70% by weight relative to the total weight of the composition.
일구현예에 따르면, 캐모마일에 대하여 물, 탄소수 1 내지 6의 유기용매 또는 이들의 혼합물을 용매로 하여 캐모마일 추출물을 수득하는 단계를 포함하는 방법으로 상기 근기능 및 운동능 강화 기능성 식품 조성물을 제조할 수 있다. 예를 들어, 탄소수 1 내지 6의 유기용매는 메탄올, 에탄올, 에틸아세테이트, 헥산 등을 포함할 수 있다.According to one embodiment, the muscle function and motor function-enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract with water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent. have. For example, the organic solvent having 1 to 6 carbon atoms may include methanol, ethanol, ethyl acetate, hexane, and the like.
일구현예에 따르면, 발명에 따른 조성물은 캐모마일에 대하여 주정 추출 또는 열수 추출하는 단계를 포함하는 방법으로 제조될 수 있다.According to one embodiment, the composition according to the invention may be prepared by a method comprising the step of extracting alcohol or hot water extracted for chamomile.
일구현예에 따르면, 주정 추출 단계에서는 10 내지 95%, 예를 들어 20 내지 80%, 예를 들어 50%주정을 사용할 수 있다. 또한, 추출 대상 부피의 2 내지 20배의 주정을 가하여 추출하는 단계를 포함할 수 있다. 또한, 예를 들어 0.5 내지 10시간, 예를 들어 2 내지 5시간 동안 추출 반응시킬 수 있으며, 예를 들어 4 내지 80℃, 예를 들어 20 내지 70℃, 예를 들어 40 내지 60℃에서 반응시킬 수 있다.According to one embodiment, 10-95%, for example 20-80%, for example 50% alcohol may be used in the alcohol extraction step. In addition, it may include the step of extracting the alcohol by adding 2 to 20 times the volume of the extraction target. It may also be extracted for example for 0.5 to 10 hours, for example 2 to 5 hours, for example at 4 to 80 ° C, for example 20 to 70 ° C, for example 40 to 60 ° C. Can be.
일구현예에 따르면, 열수 추출 단계는 추출 대상 부피의 2 내지 20배의 물을 가하여 추출하는 단계를 포함할 수 있다. 또한, 예를 들어 0.5 내지 12시간, 예를 들어 2 내지 6시간 동안 추출 반응시킬 수 있으며, 예를 들어 4 내지 121℃, 예를 들어 50 내지 121℃, 예를 들어 80 내지 121℃에서 반응시킬 수 있다.According to one embodiment, the hydrothermal extraction step may include extracting by adding 2 to 20 times the volume of the extraction target volume of water. It can also be extracted for example for 0.5 to 12 hours, for example 2 to 6 hours, for example at 4 to 121 ° C, for example 50 to 121 ° C, for example 80 to 121 ° C. Can be.
일구현예에 따르면, 캐모마일으로부터 아임계 추출법, 초임계 유체 추출법 또는 초고압 추출법을 사용하여 캐모마일 추출물을 수득하는 단계를 포함하는 방법으로 상기 근기능 및 운동능 강화 기능성 식품 조성물을 제조할 수 있다.According to one embodiment, the muscle function and exercise enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract from chamomile using subcritical extraction, supercritical fluid extraction or ultrahigh pressure extraction.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily practice the present invention. As those skilled in the art would realize, the described embodiments may be modified in various different ways, all without departing from the spirit or scope of the present invention.
실시예 1: 열수 추출 Example 1: Hot Water Extraction
캐모마일 100g에 증류수 1,500ml을 가한 후 환류냉각장치를 부착한 히팅 맨틀(heating mantle, Extraction Rota-Mantle/KBT)을 이용하여 95℃에서 4시간 동안 열수 추출하고 이를 여과한 후 농축하고 동결건조하여 캐모마일 추출물을 수득하였다.After adding 1,500 ml of distilled water to 100 g of chamomile, using a heating mantle equipped with a reflux cooling system (heating mantle, Extraction Rota-Mantle / KBT), the hot water was extracted at 95 ° C. for 4 hours, filtered, concentrated, and lyophilized. An extract was obtained.
실시예 2: 주정 추출Example 2: Alcohol Extraction
캐모마일 100g에 각각의 10%, 30%, 50%, 70%, 90% 주정 1,500ml을 가한 후, 환류냉각장치를 부착한 히팅 맨틀(heating mantle, Extraction Rota-Mantle/KBT)을 이용하여 70℃에서 4시간 동안 주정 추출하고 이를 여과한 후 농축하여 추출용매를 제거하고 동결건조하여 캐모마일 추출물을 수득하였다.After adding 1,500 ml of 10%, 30%, 50%, 70%, 90% spirits to 100 g of chamomile, 70 ° C using a heating mantle (Extraction Rota-Mantle / KBT) equipped with a reflux cooling device. Extraction of alcohol for 4 hours at, filtered and concentrated to remove the extraction solvent and lyophilized to obtain a chamomile extract.
실시예 3: 메탄올 추출Example 3: Methanol Extraction
메탄올을 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 캐모마일 추출물을 수득하였다.Chamomile extract was obtained in the same manner as in Example 2 except that methanol was used.
실시예 4: 에틸아세테이트 추출Example 4: Ethyl Acetate Extraction
에틸아세테이트을 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 캐모마일 추출물을 수득하였다.Chamomile extract was obtained in the same manner as in Example 2, except that ethyl acetate was used.
실시예 5: 헥산 추출Example 5: Hexane Extraction
헥산을 사용한 것을 제외하고는 실시예 2와 동일한 방법으로 캐모마일 추출물을 수득하였다.Chamomile extract was obtained in the same manner as in Example 2 except that hexane was used.
실시예 6: 초고압 추출Example 6 Ultra High Pressure Extraction
캐모마일 18%, 에탄올 76mL을 폴리에틸렌(polyethylene) 팩에 넣고 밀봉한 후 초고압 추출장치(Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan)를 이용하여 추출하였다. 초고압 추출조건으로 추출압력 320MPa, 추출시간 5분으로 설정하였다. 추출된 시료는 여과한 후 농축하여 추출용매를 제거하고, 동결건조하여 캐모마일 추출물을 수득하였다.Chamomile 18%, ethanol 76mL was put in a polyethylene pack and sealed and extracted using an ultrahigh pressure extractor (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan). The extraction pressure was set to 320MPa and the extraction time was 5 minutes as the ultrahigh pressure extraction condition. The extracted sample was filtered and concentrated to remove the extraction solvent, and lyophilized to obtain a chamomile extract.
실시예 7: 초임계 추출Example 7: Supercritical Extraction
캐모마일을 시료 카트리지에 충전하고 초임계 추출장치(SFX 3560, Isco Inc., Lincoln, NE, USA)를 이용하여 추출하였다. 초임계 유체 추출조건은 추출압력 20MPa, 추출온도 60℃, 초임계 이산화탄소의 유속 60mL/분, 추출시간 60분으로 설정하였다. 초임계 유체 추출이 완료되면, 추출장치의 압력을 낮추어 초임계 유체 상태를 해제하여 캐모마일 추출물을 수득하였다. Chamomile was charged to a sample cartridge and extracted using a supercritical extractor (SFX 3560, Isco Inc., Lincoln, NE, USA). Supercritical fluid extraction conditions were set to extraction pressure 20MPa, extraction temperature 60 ℃, flow rate of supercritical carbon dioxide 60mL / min, extraction time 60 minutes. When the supercritical fluid extraction was completed, the pressure of the extractor was lowered to release the supercritical fluid state to obtain a chamomile extract.
실험예 1: mTOR 활성Experimental Example 1: mTOR Activity
실시예 1에 따른 각각의 추출물에 대한 mTOR 활성을 평가하였다. mTOR는 근육 단백질 합성기전을 조절하는 역할을 하는 단백질로서, mTOR의 활성을 확인함으로써 근육량의 향상을 확인할 수 있다. 먼저, 근육모세포주인 L6 세포(ATCC)를 110% 우태아혈청(FBS; Hyclone, Logan, UT, USA)이 함유된 Dulbecco's modified Eagle's media(DMEM; Hyclone)와 함께 6-웰 플레이트에 2 Х 10 5cell/mL이 되도록 접종 후 배양하였다. 세포 밀도가 약 80 내지 85%가 되었을 때, 웰에 있는 배지를 제거하고 2% 말 혈청(HS; Hyclone)이 함유된 DMEM(Hyclone)으로 교환하여 L6 세포를 근관세포(myotube)로 분화시켰다. 2일에 한 번씩 새로운 배지로 교체하여 총 6일 동안 분화를 진행하였다. 분화 후, 50ng/mL의 TNF-α가 함유된 DMEM 배지에 상기 실시예 1에서 제조한 추출물을 100 또는 200ug/mL의 농도로 녹인 후, 세포에 처리하였다. 6시간 후, TRIzol시약(Takara, Osaka, Japan)을 사용하여 총 RNA를 분리하였다. 분리한 총 RNA는 나노드랍(NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, MA, USA)을 이용하여 정량하였다. 그 결과는 표 1에 나타내었다.MTOR activity for each extract according to Example 1 was evaluated. mTOR is a protein that plays a role in regulating the mechanism of muscle protein synthesis, and can confirm the improvement of muscle mass by confirming the activity of mTOR. First, a muscle cell master L6 cells (ATCC) 110% fetal calf serum 2 Х 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80-85%, the medium in the wells was removed and exchanged for DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) to differentiate L6 cells into myotubes. Once every two days, the cells were replaced with fresh medium for a total of six days of differentiation. After differentiation, the extract prepared in Example 1 was dissolved in DMEM medium containing 50ng / mL of TNF-α at a concentration of 100 or 200ug / mL, and then treated to cells. After 6 hours, total RNA was isolated using TRIzol reagent (Takara, Osaka, Japan). Total RNA isolated was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, Mass., USA. The results are shown in Table 1.
또한, 실시예 1에 따른 물질을 100 또는 300 ug/mL 농도로 세포에 처리한 결과는 도 1에 나타내었다.In addition, the results of treatment of cells with a substance according to Example 1 at a concentration of 100 or 300 ug / mL are shown in FIG. 1.
Figure PCTKR2019002740-appb-img-000001
Figure PCTKR2019002740-appb-img-000001
표 1 및 도 1에 나타난 바와 같이, 본 발명의 실시예에 따른 물질로 인하여 근육 단백질의 성장이 유도될 수 있음을 확인할 수 있다.As shown in Table 1 and Figure 1, it can be seen that the growth of muscle proteins can be induced by the material according to an embodiment of the present invention.
실험예 2: PPARδ 활성Experimental Example 2: PPARδ Activity
실시예 1에 따른 추출물에 대한 PPARδ 활성을 평가하기 위하여, COS7 세포(ATCC)를 10% FBS(Gibco)가 함유된 DMEM 배지에 24-well 플레이트에 1Х10 5cell/mL이 되도록 넣었다. 세포밀도가 약 80~85%가 되었을 때, Lipofector EXT(Aptabio)를 사용하여 항염증 효과를 확인하기 위해 PPARδ 형질전환을 유도하였으며 형질전환 후, 각 추출물을 10㎍/mL의 농도로 함께 세포에 24시간 처리하였다. 그리고 luciferase assay kit(Promega)를 사용하여 luciferase activity를 평가하였다.In order to evaluate PPARδ activity for the extract according to Example 1, COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) in a 24-well plate at 1Х10 5 cells / mL. When the cell density reached about 80-85%, Lipofector EXT (Aptabio) was used to induce PPARδ transformation to identify anti-inflammatory effects. After transformation, each extract was added to the cells together at a concentration of 10 ㎍ / mL. 24 hours treatment. And luciferase activity was evaluated using luciferase assay kit (Promega).
PPARδ는 지방조직에서 세포분화, 간 조직에서의 당 생성과 관련할 수 있는 단백질로, PPARδ의 활성을 확인함으로써 운동 능력의 향상을 확인할 수 있다. 결과는 표 2에 나타내었다.PPARδ is a protein that may be associated with cell differentiation in adipose tissue and sugar production in liver tissue. As a result, PPARδ may be confirmed to improve motor performance by confirming the activity of PPARδ. The results are shown in Table 2.
또한, 실시예 1에 따른 물질을 25 또는 50ug/mL로 세포에 처리한 결과는 도 2에 나타내었다.In addition, the results of treating the cells at 25 or 50 ug / mL according to Example 1 are shown in FIG. 2.
Figure PCTKR2019002740-appb-img-000002
Figure PCTKR2019002740-appb-img-000002
표 2 및 도 2에 나타난 바와 같이, 본 발명의 실시예 1에 따른 물질로 인하여 운동 능력이 향상됨을 확인할 수 있다.As shown in Table 2 and Figure 2, it can be seen that the athletic performance is improved due to the material according to Example 1 of the present invention.
실험예 3: PGC-1α 활성Experimental Example 3: PGC-1α Activity
실시예 1에 따른 추출물에 대한 PGC-1α 활성을 평가하기 위하여, COS7 세포(ATCC)를 10% FBS(Gibco)가 함유된 DMEM 배지에 24-well 플레이트에 1Х10 5cell/mL이 되도록 넣었다. 세포밀도가 약 80~85%가 되었을 때, Lipofector EXT(Aptabio)를 사용하여 항염증 효과를 확인하기 위해 peroxisome proliferator-activated receptor gamma coactivator-1 alpha(PGC-1α) 형질전환을 유도하였으며 형질전환 후, 각 추출물을 10㎍/mL의 농도로 함께 세포에 24시간 처리하였다. 그리고 luciferase assay kit(Promega)를 사용하여 luciferase activity를 평가하였다. In order to evaluate PGC-1α activity on the extract according to Example 1, COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) to 1Х10 5 cells / mL in 24-well plates. When the cell density reached about 80-85%, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) transformation was induced to identify anti-inflammatory effects using Lipofector EXT (Aptabio). Each extract was treated with cells at a concentration of 10 μg / mL for 24 hours. And luciferase activity was evaluated using luciferase assay kit (Promega).
PGC-1α는 당 조절 및 미토콘드리아 기능 복제와 관련한 단백질로서 PGC-1α의 활성을 확인함으로써 운동 능력의 향상을 확인할 수 있다. 결과는 표 3에 나타내었다.PGC-1α is a protein related to glycemic regulation and mitochondrial function replication, which can confirm the improvement of exercise ability by confirming the activity of PGC-1α. The results are shown in Table 3.
또한, 실시예 1에 따른 물질을 25 또는 50ug/mL로 세포에 처리한 결과는 도 3에 나타내었다.In addition, the results of treating the cells at 25 or 50 ug / mL according to Example 1 are shown in FIG. 3.
Figure PCTKR2019002740-appb-img-000003
Figure PCTKR2019002740-appb-img-000003
표 3 및 도 3에 나타난 바와 같이, 본 발명의 실시예 1에 따른 물질로 인하여 운동 능력이 향상됨을 확인할 수 있다.As shown in Table 3 and Figure 3, it can be seen that the athletic performance is improved due to the material according to Example 1 of the present invention.
실험예 4: 근 단백질 분해 억제 활성Experimental Example 4: Muscle protein degradation inhibitory activity
실시예 1의 근 단백질 분해 억제 활성을 확인하기 위하여, atrogin-1, MuRF1및 β-actin의 발현을 확인하였다. atrogin-1은 근육파괴단백질로서 근육이 손실될 때 활성화되는 유전자이고, MuRF1은 근육 내의 근육분해효소 단백질이며, β-actin은 근육을 구성하는 단백질로서 미오신과 함께 근육의 수축과 이완을 일으킨다.In order to confirm the muscle protein degradation inhibitory activity of Example 1, the expression of atrogin-1, MuRF1 and β-actin was confirmed. atrogin-1 is a muscle breakdown protein that is activated when muscle is lost, MuRF1 is a muscle degrading enzyme protein, and β-actin is a protein that makes up muscle, which causes muscle contraction and relaxation with myosin.
먼저, 근육모세포주인 L6 세포(ATCC)를 110% 우태아혈청(FBS; Hyclone, Logan, UT, USA)이 함유된 Dulbecco's modified Eagle's media(DMEM; Hyclone)와 함께 6-웰 플레이트에 2Х10 5cell/mL이 되도록 접종 후 배양하였다. 세포 밀도가 약 80 내지 85%가 되었을 때, 웰(well)에 있는 배지를 제거하고 2% 말 혈청(HS; Hyclone)이 함유된 DMEM(Hyclone)으로 교환하여 L6 세포를 근관세포(myotube)로 분화시켰다. 2일에 한 번씩 새로운 배지로 교체하여 총 6일 동안 분화를 진행하였다. 분화 후, 50 ng/mL의 TNF-α가 함유된 DMEM 배지에 상기 실시예 1에서 제조한 캐모마일 추출물을 100 또는 200ug/mL의 농도로 녹인 후, 세포에 처리하였다. 6시간 후, TRIzol시약(Takara, Osaka, Japan)을 사용하여 총 RNA를 분리하였다. 분리한 총 RNA는 나노드랍(NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, MA, USA)을 이용하여 정량하였다. 16uL RNA를 정량하여, 역전사효소 프리믹스(Reverse Transcriptase Premix, ELPIS-Biotech)와 혼합하여 PCR 기계(Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA)를 이용하여 42℃, 55분, 70℃, 15분의 조건에서 cDNA로 합성하였다. 합성된 cDNA 중 4 uL의 cDNA, 하기의 특정 프라이머쌍(Bioneer, Deajeon, Korea), 및 PCR 프리믹스(ELPIS-Biotech)를 혼합하여 PCR 시료를 제조한 뒤, 95℃에서 30초, 60℃에서 1분, 72℃에서 1분을 30번 반복하여 PCR을 수행하였다.First, muscle cells own, the L6 cells (ATCC) 110% fetal bovine serum (FBS; Hyclone, Logan, UT , USA) Dulbecco's modified Eagle's media (DMEM; Hyclone) is contained 2Х10 in 6-well plates with 5 cell / After inoculation to mL was incubated. When the cell density is about 80-85%, the medium in the wells is removed and exchanged for DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) to convert L6 cells into myotubes. Differentiated. Once every two days, the cells were replaced with fresh medium for a total of six days of differentiation. After differentiation, the chamomile extract prepared in Example 1 was dissolved in DMEM medium containing 50 ng / mL of TNF-α at a concentration of 100 or 200 ug / mL, and then treated to cells. After 6 hours, total RNA was isolated using TRIzol reagent (Takara, Osaka, Japan). Total RNA isolated was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, Mass., USA. 16 uL RNA was quantified and mixed with Reverse Transcriptase Premix (ELPIS-Biotech) using a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA) at 42 ° C, 55 minutes, 70 CDNA was synthesized at 15 ° C. for 15 minutes. PCR samples were prepared by mixing 4 uL of the cDNA, specific primer pairs (Bioneer, Deajeon, Korea), and PCR premix (ELPIS-Biotech) below in the synthesized cDNA, and then, at 95 ° C for 30 seconds and at 60 ° C. PCR was performed by repeating 30 minutes for 1 minute at 72 ° C.
PCR 결과 증폭된 cDNA를 1.5% 아가로즈 젤로 전기영동으로 분리하였으며, G;BOX EF 영상화 시스템(Syngene, Cambridge, UK)을 이용하여 cDNA 밴드를 확인하였다. 사용한 서열은 표 4에 나타내었으며, 그 결과를 도 4에 나타내었다.The cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 4, and the results are shown in FIG.
Figure PCTKR2019002740-appb-img-000004
Figure PCTKR2019002740-appb-img-000004
도4에 나타난 바와 같이, 캐모마일 추출물을 처리함에 따라 L6 근육세포에서 atrogin-1 및 MuRF-1의 mRNA 발현이 감소함을 알 수 있다. 이는 본 발명의 캐모마일 추출물이 근육세포 내에서 근 단백질 분해를 억제하는 능력이 우수하다는 것을 의미한다.As shown in Figure 4, it can be seen that the mRNA expression of atrogin-1 and MuRF-1 is reduced in L6 muscle cells as the chamomile extract is treated. This means that the chamomile extract of the present invention has an excellent ability to inhibit muscle protein degradation in muscle cells.
실험예 5: 미토콘드리아 생합성 촉진 및 근육 분화 촉진 활성Experimental Example 5: Mitochondrial biosynthesis promoting and muscle differentiation promoting activity
실시예 1의 근 미토콘드리아 생합성 촉진 및 근육 분화 촉진 활성을 확인하기 위하여, myogenin, NRF1 및 Tfam의 발현을 확인하였다. Myogenin은 근관세포로의 분화와 성숙을 제어하고, NRF1는 미토콘드리아 단백질 생성에 관여하며, Tfam은 미토콘드리아 DNA 전사에 관여한다.In order to confirm the muscle mitochondrial biosynthesis promoting and muscle differentiation promoting activity of Example 1, the expression of myogenin, NRF1 and Tfam was confirmed. Myogenin controls differentiation and maturation into myotubes, NRF1 is involved in mitochondrial protein production, and Tfam is involved in mitochondrial DNA transcription.
먼저, 근육모세포주인 L6 세포(ATCC)를 110% 우태아혈청(FBS; Hyclone, Logan, UT, USA)이 함유된 Dulbecco's modified Eagle's media(DMEM; Hyclone)와 함께 6-웰 플레이트에 2 Х 10 5cell/mL이 되도록 접종 후 배양하였다. 세포 밀도가 약 80 내지 85%가 되었을 때, 웰(well)에 있는 배지를 제거하고 2% HS가 함유된 DMEM (Hyclone)에 상기 실시예 1에서 제조한 캐모마일 추출물을 100 또는 200ug/mL의 농도로 녹인 후, 세포에 처리하여 근관세포로 분화를 유도하였다. 이 때, 시료 대신 0.01% DMSO를 처리한 군을 대조군으로 사용하였다. 이 과정을 2일간 3회 반복, 총 6일 동안 진행하여 분화시킨 후, TRIzol시약(Takara, Osaka, Japan)을 사용하여 총 RNA를 분리하였다. 분리한 총 RNA는 나노드랍(NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, MA, USA)을 이용하여 정량하였다. 16uL RNA를 정량하여, 역전사효소 프리믹스(Reverse Transcriptase Premix, ELPIS-Biotech)와 혼합하여 PCR 기계(Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA)를 이용하여 42℃, 55분, 70℃, 15분의 조건에서 cDNA로 합성하였다. 합성된 cDNA 중 4uL의 cDNA, 하기의 특정 프라이머쌍(Bioneer, Deajeon, Korea), 및 PCR 프리믹스(ELPIS-Biotech)를 혼합하여 PCR 시료를 제조한 뒤, 95℃에서 30초, 60℃에서 1분, 72℃에서 1분을 30번 반복하여 PCR을 수행하였다.First, a muscle cell master L6 cells (ATCC) 110% fetal calf serum 2 Х 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80 to 85%, the medium in the well was removed and the chamomile extract prepared in Example 1 was added to DMEM (Hyclone) containing 2% HS at a concentration of 100 or 200 ug / mL. After thawing, the cells were treated to induce differentiation into root canal cells. At this time, the group treated with 0.01% DMSO instead of the sample was used as a control. This process was repeated three times for two days, followed by differentiation for a total of six days, and total RNA was isolated using TRIzol reagent (Takara, Osaka, Japan). Total RNA isolated was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, Mass., USA. 16 uL RNA was quantified and mixed with Reverse Transcriptase Premix (ELPIS-Biotech) using a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA) at 42 ° C, 55 minutes, 70 CDNA was synthesized at 15 ° C. for 15 minutes. In the synthesized cDNA, 4uL cDNA, the following specific primer pairs (Bioneer, Deajeon, Korea), and PCR premix (ELPIS-Biotech) were mixed to prepare a PCR sample, followed by 30 minutes at 95 ° C and 1 minute at 60 ° C PCR was performed by repeating 1 minute at 72 ° C. for 30 times.
PCR 결과 증폭된 cDNA를 1.5% 아가로즈 젤로 전기영동으로 분리하였으며, G;BOX EF 영상화 시스템(Syngene, Cambridge, UK)을 이용하여 cDNA 밴드를 확인하였다. 사용한 서열은 표 5에 나타내었으며, 그 결과를 도 5에 나타내었다.The cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 5, and the results are shown in FIG.
Figure PCTKR2019002740-appb-img-000005
Figure PCTKR2019002740-appb-img-000005
도 5에 나타난 바와 같이, 캐모마일 추출물을 처리함에 따라 L6 근육세포에서 myogenin, NRF1, Tfam의 mRNA 발현이 증가함을 알 수 있다. 이는 본 발명의 캐모마일 추출물이 근육세포 내에서 근육 분화 촉진 및 미토콘드리아 생합성 능력이 우수하다는 것을 의미한다.As shown in Figure 5, it can be seen that the mRNA expression of myogenin, NRF1, Tfam in L6 muscle cells increases as the chamomile extract is treated. This means that the chamomile extract of the present invention is excellent in promoting muscle differentiation and mitochondrial biosynthesis in muscle cells.
상기한 바와 같이, 실험예 1 내지 5에 따른 결과를 정리하면 표 6 및 7과 같다.As described above, the results according to Experimental Examples 1 to 5 are summarized in Tables 6 and 7.
Figure PCTKR2019002740-appb-img-000006
Figure PCTKR2019002740-appb-img-000006
또한, 실험예 4 내지 8의 결과를 정리하면 표 7과 같다.In addition, the results of Experimental Examples 4 to 8 are summarized in Table 7.
Figure PCTKR2019002740-appb-img-000007
Figure PCTKR2019002740-appb-img-000007
상기 결과에서 확인할 수 있는 바와 같이, 본 발명에 따르면 미토콘드리아 및 근육 세포의 합성을 증가시키고, 근육의 위축을 억제함으로써 근육 운동의 효율성을 향상시킬 수 있고, 피로를 적게 느끼게 하는 효과를 나타낼 수 있음을 확인할 수 있다.As can be seen from the above results, according to the present invention, it is possible to increase the synthesis of mitochondria and muscle cells and to suppress the muscle atrophy, thereby improving the efficiency of muscle movement and reducing the fatigue. You can check it.
이상의 설명은 본 발명의 기술 사상을 예시적으로 설명한 것에 불과한 것으로서, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자라면 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 다양한 수정 및 변형이 가능하다. 또한, 본 발명에 개시된 실시 예들은 본 발명의 기술 사상을 한정하기 위한 것이 아니라 설명하기 위한 것이고, 이러한 실시 예에 의하여 본 발명의 기술 사상의 범위가 한정되는 것은 아니다. 본 발명의 보호 범위는 아래의 청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 할 것이다.The above description is merely illustrative of the technical idea of the present invention, and those skilled in the art may make various modifications and changes without departing from the essential characteristics of the present invention. In addition, the embodiments disclosed in the present invention are not intended to limit the technical spirit of the present invention but to describe the present invention, and the scope of the technical idea of the present invention is not limited by these embodiments. The protection scope of the present invention should be interpreted by the following claims, and all technical ideas within the equivalent scope should be interpreted as being included in the scope of the present invention.

Claims (5)

  1. 캐모마일 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물.Muscle function and athletic function functional food composition comprising chamomile extract.
  2. 제1항에 있어서, 조성물 총 중량에 대하여, 캐모마일 추출물을 0중량% 초과 100중량% 이하 포함하는 것인, 근기능 및 운동능 강화 기능성 식품 조성물.According to claim 1, wherein the total weight of the composition, containing more than 0% by weight 100% by weight of chamomile extract, muscle function and athletic function functional food composition.
  3. 제1항에 있어서, 상기 식품 조성물은 근육 관련 질환의 예방 또는 개선용 조성물로서, 상기 근육 관련 질환은 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증(myasthenia), 근경직증(myotonia), 근위축성 축삭경화증(amyotrophic lateral sclerosis), 악액질(cachexia), 근육감소증(sarcopenia)으로 이루어지는 군으로부터 선택되는 하나 이상인 것인, 근기능 및 운동능 강화 기능성 식품 조성물.The method of claim 1, wherein the food composition is a composition for preventing or ameliorating muscle-related diseases, wherein the muscle-related diseases include atony, muscular atrophy, muscular dystrophy, muscle degeneration, and work history. Myasthenia, myotonia, myotonia, amyotrophic lateral sclerosis (amyotrophic lateral sclerosis), cachexia, sarcopenia is one or more selected from the group consisting of, muscle function and athletic function functional food composition.
  4. 캐모마일에 대하여, 물, 탄소수 1 내지 6의 유기용매 또는 이들의 혼합물을 용매로 하여 캐모마일 추출물을 수득하는 단계를 포함하는 근기능 및 운동능 강화 기능성 식품 조성물의 제조방법.For chamomile, a method for preparing muscle function and exercise-enhancing functional food composition comprising the step of obtaining chamomile extract using water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent.
  5. 캐모마일로부터 아임계 추출법, 초임계 유체 추출법 또는 초고압 추출법으로 캐모마일 추출물을 수득하는 단계를 포함하는 것인, 근기능 및 운동능 강화 기능성 식품 조성물의 제조방법.Comprising the step of obtaining the chamomile extract from chamomile by subcritical extraction method, supercritical fluid extraction method or ultra-high pressure extraction method, muscle function and exercise performance enhancing functional food composition.
PCT/KR2019/002740 2018-03-09 2019-03-08 Functional food composition for enhancing muscular function and mobility and comprising chamomile extract, and method for preparing same WO2019172714A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180027742A KR102066388B1 (en) 2018-03-09 2018-03-09 Functional food composition for enhancing myofunction and athletic function comprising chamomile extract and manufacturing method thereof
KR10-2018-0027742 2018-03-09

Publications (1)

Publication Number Publication Date
WO2019172714A1 true WO2019172714A1 (en) 2019-09-12

Family

ID=67846781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002740 WO2019172714A1 (en) 2018-03-09 2019-03-08 Functional food composition for enhancing muscular function and mobility and comprising chamomile extract, and method for preparing same

Country Status (2)

Country Link
KR (1) KR102066388B1 (en)
WO (1) WO2019172714A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651910B1 (en) 2021-03-08 2024-03-27 주식회사 에치와이 Composition for Preventing or Aemliorating Muscular Diseases Comprising Lactobacillus Plantarum HY7715

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920010389B1 (en) * 1984-03-16 1992-11-27 아스타 메디카 아크티엔게젤샤프트 Process for the production of camomile extracts rich in flavones
JP2010534697A (en) * 2007-07-31 2010-11-11 フレセニウス・カビ・ドイツチユラント・ゲーエムベーハー Cachexia prevention supplement
US20150283189A1 (en) * 2014-04-04 2015-10-08 Biologische Heilmittel Heel Gmbh Medicament for treating muscle and skeletal diseases
KR20170044737A (en) * 2014-08-27 2017-04-25 에스더블유엠 룩셈부르크 에스.에이.알.엘. Method for making reconstituted plant material using extrusion or molding processes and products so obtained
CN107308407A (en) * 2017-06-29 2017-11-03 芜湖凌梦电子商务有限公司 A kind of effective composite essential oil for alleviating muscle cramp and joint pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920010389B1 (en) * 1984-03-16 1992-11-27 아스타 메디카 아크티엔게젤샤프트 Process for the production of camomile extracts rich in flavones
JP2010534697A (en) * 2007-07-31 2010-11-11 フレセニウス・カビ・ドイツチユラント・ゲーエムベーハー Cachexia prevention supplement
US20150283189A1 (en) * 2014-04-04 2015-10-08 Biologische Heilmittel Heel Gmbh Medicament for treating muscle and skeletal diseases
KR20170044737A (en) * 2014-08-27 2017-04-25 에스더블유엠 룩셈부르크 에스.에이.알.엘. Method for making reconstituted plant material using extrusion or molding processes and products so obtained
CN107308407A (en) * 2017-06-29 2017-11-03 芜湖凌梦电子商务有限公司 A kind of effective composite essential oil for alleviating muscle cramp and joint pain

Also Published As

Publication number Publication date
KR102066388B1 (en) 2020-01-15
KR20190107249A (en) 2019-09-19

Similar Documents

Publication Publication Date Title
WO2019172712A1 (en) Functional food composition for enhancing muscular function and mobility and comprising lotus leaf extract, and method for preparing same
Recio et al. Immunmodulatory and antiproliferative properties of Rhodiola species
WO2021040371A1 (en) Anti-inflammatory composition
WO2021153876A1 (en) Differentiation method from human adipose-derived mesenchymal stem cells to dermal papilla cells
WO2018043864A1 (en) Leuconostoc holzapfelii strain having hair loss prevention, hair growth promotion or sexual function improvement effects, and composition comprising same
WO2021261632A1 (en) Novel faecalibacterium prausnitzii strain eb-fpdk11 and use thereof
Cui et al. An oleanolic acid derivative reduces denervation-induced muscle atrophy via activation of CNTF-mediated JAK2/STAT3 signaling pathway
WO2019059606A1 (en) Composition containing amomum villosum extract for prevention, alleviation, or treatment of obesity
WO2019172714A1 (en) Functional food composition for enhancing muscular function and mobility and comprising chamomile extract, and method for preparing same
WO2017030383A2 (en) Pharmaceutical composition for preventing or treating muscular dystrophy including bakuchiol as active ingredient
WO2017086744A1 (en) Pharmaceutical composition for preventing and treating cancer or cancer metastasis, containing pstl1 protein as active ingredient
EP2774617B1 (en) Medical composition containing stauntonia hexaphylla extract
WO2021141237A1 (en) Composition for reinforcing function of stem cell
WO2022240243A1 (en) Skin-whitening composition containing nanovesicles
WO2023158024A1 (en) Composition for prevention, amelioration or treatment of inflammatory bowel disease comprising isodon excisus (max.) kudo-derived compound as active ingredient
Cui et al. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways
KR102383026B1 (en) Composition comprising compound from extract of Dryopteris crassirhizoma for preventing or treating coronavirus infection
WO2021162463A1 (en) Composition for preventing, treating, and alleviating atopic dermatitis comprising flavone-resveratrol conjugate compound
WO2010058936A2 (en) Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing ortho-dihydroxyisoflavone derivatives
WO2021261631A1 (en) Novel picalibacterium prosnich eb-fpdk9 strain and uses thereof
WO2022239916A1 (en) Novel bifidobacterium longum strain and use thereof
Liang et al. Effect of puerarin on TIMP3, MMP-9 expression and methylation in chondrocytes of rat osteoarthritis
WO2018056585A1 (en) Composition for reinforcing skin barrier function comprising card18 expression-promoting material, and method for screening card18 promoting material
WO2024147560A1 (en) Immuno-anticancer composition comprising toxicodendron vernicifluum extract and cytokine killer cells
US20090136600A1 (en) Method for alleviating chemotherapy side effects using extract of dioscorea sp.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19763728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19763728

Country of ref document: EP

Kind code of ref document: A1